News

Chambers USA recognizes Scott M. Lassman as a leading FDA regulatory lawyer

Chambers USA recently recognized Scott M. Lassman as a leading attorney (Band 2) in the category of Healthcare: Pharmaceutical/Medical Products Regulatory. Chambers USA specifically highlighted his ability to provide practical solutions to complex regulatory issues, his efficiency, and his "deep knowledge of Hatch-Waxman."

Categories: Honors

New, Emerging and Continually Interesting Biosimilars Issues

Scott M. Lassman is scheduled to speak about New, Emerging, and Continually Interesting Issues at the Food and Drug Law Institute's Introduction to Biologics and Biosimilars Law and Regulation conference on April 1, 2020.

Categories: Speaking

Scott M. Lassman Named in Who's Who Legal's Life Sciences 2020 Guide

Scott M. Lassman was recently recognized by Who's Who Legal as a recommended regulatory attorney in its Life Sciences 2020 guide.

The Who's Who Legal research process is based on recommendations and feedback from eminent private practitioners in the sector as well as from corporate counsel.

Categories: Honors

Exclusivity Webinar

On February 27, 2020, Scott M. Lassman presented a webinar on recent developments affecting exclusivity for drugs and biological products. The webinar was hosted by FDANews.

Categories: Speaking

Scott M. Lassman Named in Who's Who Legal's Healthcare 2020 Guide

Scott M. Lassman recently was recognized as a leading regulatory attorney in the Who's Who Legal Healthcare 2020 guide.

The Who's Who Legal research process is based on recommendations and feedback from eminent private practitioners in the sector as well as from corporate counsel.

Biosimilars at the Bar

Scott M. Lassman participated in a panel discussion entitled Biosimilars at the Bar at AAM's GRx+Biosims Conference on November 4, 2019. The panel discussed recent legal developments affecting biosimilars, including interchangeability, labeling carve-outs, enhancements to the Purple Book and regulatory pathways for approval of "biobetters."

Categories: Speaking

LMG Life Sciences: Scott M. Lassman Recognized As a Regulatory Law Star for 2019

Scott M. Lassman recently was recognized by LMG Life Sciences as a Regulatory Law Star in the areas of pharmaceutical and medical device regulatory law for 2019.

LMG Life Sciences evaluates attorneys on the basis of case evidence, peer feedback and client feedback.

Categories: Honors

New Developments in Biologics and Biosimilars

Scott M. Lassman is scheduled to speak about New, Emerging, and Continually Interesting Issues at the Food and Drug Law Institute's Introduction to Biologics and Biosimilars Law and Regulation on October 2, 2019 in Washington, D.C.

Categories: Speaking

Best Lawyers: Scott M. Lassman Recognized in the Areas of FDA Law and Administrative Law

Scott M. Lassman recently was recognized by The Best Lawyers in America as one of the leading lawyers in America in the categories of FDA Law and Administrative/Regulatory Law.

Best Lawyers' recognitions are based purely on the feedback received from lawyers already highlighted in the publication.

Categories: Honors

Lassman Law+Policy Client Braeburn Prevails in District Court on 3-Year Exclusivity Dispute

Lassman Law+Policy was privileged to represent Braeburn, Inc. (with co-counsel Goodwin) in securing this U.S. District Court ruling overturning an FDA decision on 3-year exclusivity as unreasonable and arbitrary and capricious. The decision, issued on July 22, 2019, orders FDA to reconsider "with deliberate speed" Braeburn's application for approval of an innovative new injectable treatment for opioid use disorder. Read all about it here.

Categories: Other News

Scott Lassman

Scott M. Lassman's Profile Image
Scott Lassman has nearly 30 years’ experience in FDA law and policy, both as an in-house attorney and in private practice. He provides strategic advice and advocacy to small, mid-size and large pharmaceutical, biotechnology and medical device companies, as well as the trade associations that represent them and the investors who fund them. His practice covers all aspects of FDA regulatory law, with a special focus on exclusivity, biosimilars, product approval and policy matters...

Read More About Scott

For More Information

  • This field is for validation purposes and should be left unchanged.